| Literature DB >> 36120132 |
Xinnan Liu1,2, Shuping Wang3, Jingyang Li4, Jingze Zhang1, Dailin Liu1.
Abstract
Chronic atrophic gastritis (CAG), a common disease of digestive system, is an extremely important cause of gastric cancer (GC). The occurrence and development of CAG involves the abnormality of multiple signaling pathways. Traditional Chinese medicines (TCMs) has the advantages of mild action, multi-target and small adverse reaction, etc., which broadens the way for the treatment of the disease, and TCMs can play a therapeutic role by regulating multiple signaling pathways. In this review, based on the related experiments of TCMs and Chinese herbal compounds in recent years, the related literatures were searched and 10 kinds of signaling pathways involved were summarized, in order to provide a reference for further research on reversing or delaying the progress of CAG and preventing gastric cancer.Entities:
Keywords: chronic atrophic gastritis; gastric cancer; signaling pathway; traditional Chinese medicines
Year: 2021 PMID: 36120132 PMCID: PMC9476726 DOI: 10.1016/j.chmed.2021.10.008
Source DB: PubMed Journal: Chin Herb Med ISSN: 1674-6384
Studies of TCMs on regulating signaling pathways of CAG and GC.
| Diseases | Chinese herbal prescriptions/ medicinal materials/ active ingredients | Signaling pathways | Target proteins | References |
|---|---|---|---|---|
| CAG | Baicalein | NF-κB | IL-8, NF-κB p65, COX-2, HSP70 | ( |
| Atractylodes lactone Ⅰ | NF-κB | NF-κB p65, COX-2, HSP70 | ( | |
| Paeoniflorin | NF-κB | NF-κB p65 | ( | |
| Clematoside | NF-κB | NF-κB p65 | ( | |
| Weiweikang Ganule | NF-κB | NF-κB p65, IL-6, IL-10 | ( | |
| Anwei Decoction | NF-κB | NF-κB p65, Bcl-2 | ( | |
| Xiangsha Liujunzi Decoction | NF-κB | NF-κB p65, IL-1, TNF-α | ( | |
| Qinghuayin Decoction | NF-κB | NF-κB, COX-2 | ( | |
| Qizhu Erzhu Ercao Decoction | NF-κB | NF-κB/p65, Cyclin E | ( | |
| PI3K/AKT/mTOR | PTEN | ( | ||
| Anwei Decoction | PI3K/AKT/mTOR | PTEN, PI3K, PDK1, AKT, XIAP | ( | |
| Ershen Sancao Decoction | PI3K/AKT/mTOR | AKT, ERK, PTEN | ( | |
| Jianpi Yiqi Decoction | Wnt/β-catenin | β-catenin, Wnt3a, c-myc, GSK-3β | ( | |
| Anwei Decoction | JAK/STAT | JAK1, STAT3, c-myc, SOCS-3 | ( | |
| Ganweibaihe Decoction | JAK/STAT | IL-2, IFN-γ, IL-4, IL-10 | ( | |
| Shuangpu Powder | TGF-β/Smad | Bcl-2, P53, PCNA, Ag-NORs, EGF, TGF-β1 | ( | |
| Astragaloside | TLRs | MyD88, TLR4, SOD | ( | |
| TLRs | TLR4, MyD88, NF-κB p65 | ( | ||
| TLRs | TLR2, TLR4, TLR5, TLR9, MyD88, TRAF6 | ( | ||
| Jianpi Qinghua Decoction | TLRs | TLR4, MyD88, NF-κB, COX-2 | ( | |
| Banxia Xiexin Decoction | Notch | Notch1, Notch2, Hes1, Jagged1 | ( | |
| GC | curcumin | PI3K/AKT/mTOR | PI3K, p-Akt | ( |
| Celastrol | PI3K/AKT/mTOR | miR-21 | ( | |
| Dihydroartemisinin | Wnt/β-catenin | Dvl2, p-GSK3β, β-catenin, Cyclin D1, GSK-3β | ( | |
| Weipixiao Decoction | Wnt/β-catenin | Lgr5, MMP-7, Wnt1, β-catenin | ( | |
| Fufang Xiyi Pulvis | Wnt/β-catenin | Wnt2 and β-catenin | ( | |
| Shenqi Yizhu decoction | Wnt/β-catenin | p-GSK3β, β-catenin | ( | |
| Zuojin Wan Pilula | Wnt/β-catenin | MMP-7 | ( | |
| Curcumin | JAK/STAT | HSP90 | ( | |
| Ursolic acid | JAK/STAT | COX-2, procaspase-3 | ( | |
| Xinwei Granule | JAK/STAT | STAT3 | ( | |
| Astragaloside IV | Hedgehog | Cyclin D1, Shh, Ptch, Gli-1 | ( | |
| Ginsenoside Rg1 | Hedgehog | Shh, Ptch, Gli-1 | ( | |
| Dihydrotanshinone | Hedgehog | MMP2, MMP9, p53, FoxO3, STAT3 | ( | |
| Curcumin | Hedgehog | Shh, Gli-1 | ( | |
| Silymarin | MAPK | Bax, p-JNK and p-p38, Bcl-2, p-ERK1/2 | ( | |
| Resveratrol | MAPK | IL-6 | ( | |
| Lycopene | MAPK | ROS, EGFR, COX2 | ( | |
| Triptonide | Notch | Notch1, RBPJ, IKKα, IKKβ, p-NF-κB | ( |
Fig. 1Pathways that represent potential targets for the treatment of chronic atrophic gastritis and gastric cancer.
Fig. 2Interaction of key factors upstream and downstream in NF-κB signaling pathway.
Fig. 3Interaction of key factors upstream and downstream in PI3K/AKT signaling pathway.
Fig. 4Interaction of key factors upstream and downstream in Wnt signaling pathway.
Fig. 5Interaction of key factors upstream and downstream in JAK/STAT signaling pathway.
Fig. 6Interaction of key factors upstream and downstream in Hedgehog signaling pathway.
Fig. 7Interaction of key factors upstream and downstream in Hippo signaling pathway.
Fig. 8Interaction of key factors upstream (A) and downstream (B) in MAPK signaling pathway.
Fig. 9Interaction of key factors upstream and downstream in TGF-β1/Smad3 signaling pathway.
Fig. 10Interaction of key factors upstream and downstream in TLRs signaling pathway.
Fig. 11Interaction of key factors upstream and downstream in Notch signaling pathway.